Teva Pharmaceutical Industries (TEVA) reported Q1 non-GAAP earnings Wednesday of $0.52 per diluted share, up from $0.48 a year earlier.
Four analysts polled by FactSet expected $0.47.
Net revenue for the quarter ended March 31 was $3.89 billion, up from $3.82 billion a year earlier.
Analysts surveyed by FactSet expected $4.06 billion.
The company said its updated full-year 2025 guidance considered the tariff and trade environment as of Wednesday.
Teva now expects 2025 non-GAAP diluted EPS of $2.45 to $2.65, compared with its previous guidance of $2.35 to $2.65. Analysts surveyed by FactSet expect $2.59. Full-year 2025 revenue is now expected to range from $16.8 billion to $17.2 billion, from its previous guidance of $16.8 billion to $17.4 billion. Analysts polled by FactSet expect $17.51 billion.
The company's shares were up 2.1% in recent premarket activity Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。